Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~10 mi. (Valenciennes, France, +226 more cities)

Centre Hospitalier de Valenciennes ( Site 0439)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

~10 mi. (Valenciennes, France, +158 more cities)

Clinique Teissier Groupe ( Site 0808)

Non-Small Cell Lung Carcinoma

olaparib, +4 more drugs

chemotherapy, +3 more types

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~14 mi. (Bruyelle, Belgium, +199 more cities)

Erasme Hospital ( Site 0376)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~14 mi. (Bruyelle, Belgium, +163 more cities)

UCL Saint-Luc - Oncologie Medicale ( Site 0357)

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer

~14 mi. (Bruyelle, Belgium, +202 more cities)

Site BE32002

CLDN18 Expression, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

modified FOLFOX6 regimen, +1 more drug

chemotherapy, +1 more type

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma

~14 mi. (Bruyelle, Belgium, +42 more cities)

Cliniques Universitaires Saint-Luc Av.

Esophageal Squamous Cell Carcinoma

cisplatin/fluorouracil regimen, +2 more drugs

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

~21 mi. (Mons, Belgium, +176 more cities)

C.I.U. Hopital Ambroise Pare ( Site 2039)

Endometrial Carcinoma, +1 more condition

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

~21 mi. (Mons, Belgium, +147 more cities)

C.I.U. Hopital Ambroise Pare ( Site 0353)

Cervical Adenocarcinoma, +2 more conditions

brachytherapy, +3 more drugs

chemotherapy, +2 more types

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

~21 mi. (Mons, Belgium, +122 more cities)

C.I.U. Hopital Ambroise Pare ( Site 1001)

Small Cell Lung Carcinoma

etoposide, +5 more drugs

chemotherapy, +3 more types

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

~27 mi. (Ronse, Belgium, +206 more cities)

Algemeen Ziekenhuis Glorieux Ronse

Non-Squamous Non-Small Cell Lung Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~35 mi. (Lille, France, +93 more cities)

Polyclinique du Bois ( Site 0458)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~35 mi. (Lille, France, +207 more cities)

Centre Oscar Lambret ( Site 0911)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types